RNS Number : 0435P
Calculus VCT PLC
05 December 2024
 

Calculus VCT plc

Half Yearly Report for the six months ended 30 September 2024

 

INVESTMENT OBJECTIVE

The Company's principal objectives for investors are to:

 

invest in a portfolio of Venture Capital Investments that will provide investment returns that are sufficient to allow the Company to maximise dividends and capital growth over the medium to long term;

 

generate sufficient returns from a portfolio of Venture Capital Investments that will provide attractive long-term returns within a tax efficient vehicle;

 

review and pay the appropriate level of dividends annually taking account of investment returns achieved and future prospects; and

 

maintain VCT status to enable qualifying investors to retain their income tax relief of up to 30 per cent. on the initial investment and receive tax-free dividends and capital growth.

 

 

FINANCIAL OVERVIEW

                                                                                                             

 

 

Financial Highlights

6 months to
30-Sep-24

 

13 months to
31-Mar-24

 

6 months to
31-Aug-23


pence

 

pence


pence

Opening net asset value

61.58

 

65.53


65.63

Capital loss

(1.74)

 

(1.26)


(1.04)

Revenue return

0.22

 

0.37


0.11

Total return1

(1.52)

 

(0.89)


(0.93)

Dividends paid

(2.77)

 

(2.95)


(2.95)

Impact of share capital movements

(0.09)

 

(0.11)


(0.20)

Closing net asset value

57.20

 

61.58


61.55

 



 

Total Shareholder value

Ordinary shares (pence per share)

Total dividends paid to 30 September 20242

26.65

Net asset value on 30 September 2024

57.20

Total shareholder value to 30 September 2024

83.85

 

 

2 total dividends paid include cumulative dividends paid since 2017

 

 

£41.29m

Total Net Assets as at 30 September 2024

57.20p

NAV per share as at 30 September 2024

£1.3m

Total cost of new and follow-on investments in the six months to 30 September 2024

1.00X

5-year total return

£5.8m

Funds raised in the six months to 30 September 2024

£2.0m

Dividends paid out in the six months to 30 September 2024

£0.5m

Shares bought back in the six months to 30 September 2024

37
Portfolio companies at period-end

 

Historical Total Return


Financial period-end

NAV at period-end

Cumulative dividends received (p)*

Total return (p)**

30 September 2024

57.20

-

                   57.20

31 August 2023

61.55

2.77

                   59.97

31 August 2022

64.61

5.72

                   62.92

31 August 2021

64.01

8.78

                   65.98

31 August 2020

64.27

11.80

                   69.00

31 August 2019

72.20

15.00

                   72.20

 

 

*     Cumulative dividends received includes all dividends received since the relevant Financial period-end to date

**   Total NAV return is equal to the sum of NAV at 30 September 2024 and cumulative dividends received



 

CHAIRMAN'S UPDATE

 

I am pleased to present your Company's results for the 6 months to 30 September 2024.

 

Performance summary

 

The Company has maintained a positive total return over a five-year period across the portfolio. The NAV at the period end was 57.20 pence per share, which, after paying the 2.77 pence dividend in August 2024, represents a small decrease of 3% since the year end.

 

The largest positive movements in the qualifying portfolio derived from the de-listing of C4X Discovery Holdings plc (now C4X Discovery Holdings Limited), an uplift in Blu Wireless Technology Limited following the conversion of a loan note in May 2024 and an uplift in Scancell plc, one of the Company's AIM-listed holdings. These combine to make a £0.6m uplift in the Company's NAV.

 

In October 2024, Chancellor Rachel Reeves announced a number of changes to how capital gains and inheritance taxes are charged. In a high tax landscape, the VCT product range remains a stable and reliable source of tax relief. The new Chancellor used the Autumn Statement as an opportunity to identify the critical role VCT schemes play in creating a positive environment for UK entrepreneurship. Offering tax free capital growth, 30% income tax relief on the value of the investment and tax-free dividend income; the Calculus VCT remains a credible and dependable tax efficient investment product for UK investors.

 

Additionally, we are pleased to report positive developments in our dividend policy, reflecting our continued confidence of our portfolio and our commitment to delivering value to our shareholders. Following careful consideration, we are increasing the annual dividend yield from 4.5% to 5%, marking a significant step in enhancing shareholder returns. Furthermore, I am delighted to introduce an interim dividend, which will provide shareholders with more frequent income distributions and align with our goal of steady and predictable returns. These changes underscore our confidence in the outlook for the business and our ability to generate sustainable growth. Please refer to the "New Dividend Target" below for further information regarding the Company's dividend policy.

 

Open Energy Market ('OEM') has continued to build on what was a strong 2023 where revenues for the year ended 31 Jan 2024 increased by 34%. As a result, OEM's performance contributed £0.1m to the Company's NAV. This has been underpinned by increasing successful traction across both the energy intensive industry (EII) sector and increasing exposure to and presence in the lucrative European market through existing blue-chip multinational customers. OEM's senior management team are in the advanced stages of finalising a two-year strategic and operational plan, underpinned by the appointment of a new head of finance and head of financial planning and analysis, as they target an exit event in early 2027.

 

Riff Raff Entertainment Limited ('Riff Raff') has developed strongly since Calculus' first investment in June 2022 and increased the NAV by a further £0.2m having recently signed a two-year 'First Look' TV deal with Newen. In August 2024, the true-crime thriller film, The Order, premiered at the Venice Film Festival. It is set to be released in the US in December 2024. Black Rabbit, a major eight-part drama series, has finished production for Netflix with Jude Law and Jason Bateman (Ozark) starring and is in post-production.

 

In September 2024, eConsult was sold to Huma Therapeutics Limited in a share-for-share deal. Huma Therapeutics is a UK based company offering a remote patient monitoring platform which advances connected care for patients and accelerates research and therapies. Although Huma Therapeutics is a large, well-funded company that recently raised $80m from investors including AstraZeneca, the share-for-share exchange resulted in a fall of £0.5m of the Company's NAV.

 

The ideas and generation market has been challenging, leading to a large number of cost-cutting drives within the industry. Wazoku Limited was required to cut costs significantly throughout the year, which in turn, hit its ability to drive strong sales. This is reflected in the valuation of the company, resulting in a £0.5m decrease in the Company's NAV.

In the 6-month period following the year-end, WheelRight was acquired by Snider, a US strategic investor and tyre trucking company. Whilst WheelRight's technology is potentially groundbreaking, it has struggled to commercialise it to a level which made the company self-sustaining. In May 2024, with the company close to exhausting its cash runway, the Snider CEO made an offer for the company in a personal capacity and through an acquisition vehicle wholly owned by him in the amount of £0.01 per share and which, in the absence of any other tangible options, was agreed by all of the company's main shareholders including Calculus. Calculus insisted on a structure that would see its £1.6m outstanding loan notes and accrued interest paid out in full over an extended period and which was also agreed with the Snider CEO in a personal capacity. This saw the loan notes assigned to the Snider CEO's corporate acquisition entity in return for which Calculus received £400k upon completion and a promissory note for the residual ca. £1.45 million obligating full repayment in two tranches within 4 years.

 

As mentioned above, the Company also converted £300k of Blu Wireless Technology Limited loan stock. Following this, in June 2024, external and internal investors led a £5m equity round into Blu Wireless Technology, with Westermo, an industrial communications provider focused on the rail industry, acting as lead strategic investor.  As part of the round, significant convertible loan notes were converted into equity, resolving a key issue as these would have substantially matured otherwise on 31 December 2024. The company is continuing to make substantial progress in both the rail defence sectors.

 

In the period to 30 September 2024, four follow-on investments were made on behalf of the qualifying portfolio and one new investment was made:

 

New investment

 

Date of Investment

Name of Investment

Location

Sector

Amount of Investment

May 2024

Engaging Works Holding Limited

United Kingdom

Technology

£666,471

 

 

Follow-on Investments

 

Date of Investment

Name of Investment

Location

Sector

Amount of Investment

May 2024

Blu Wireless Technology Limited

United Kingdom

Technology

£32,603
(Conversion of loan note)

July 2024

Invizius Limited

United Kingdom

Healthcare

£111,000

August 2024

Brouhaha Entertainment Limited

United Kingdom

Entertainment

£250,000

August 2024

Optalitix Limited

United Kingdom

Technology

£281,894

 

 

We believe the portfolio is well positioned to continue to provide long term growth to shareholders and that our Investment Manager is similarly positioned to exploit these opportunities.


 

Buybacks

 

During the period, the Company bought back and cancelled 833,854 Ordinary shares. The Company continues to review opportunities to carry out share buybacks at a discount of no greater than 5% to NAV.

 

Since the period end, the Company has bought back and cancelled a further 517,241 shares.

 

Dividends

 

As mentioned above, a dividend was paid on 29 August 2024 of 2.77 pence per eligible Ordinary share. It is expected that the next dividend will be paid in March 2025 as announced below

 

New Dividend Target

 

As mentioned in the Chairman's Statement, the Company is targeting a regular dividend yield in each financial year of 5% of the Net Asset Value per share at the start of that financial year. The Company is due to pay this dividend in two instalments; an interim dividend of 2% of the NAV, which is due to be paid in March 2025 and a final dividend of 3% of the NAV, which is due to be paid in October 2025.

 

The board are pleased to declare an interim dividend of 1.14p per share which will be paid to shareholders on 26 March 2025. Shareholders on the register as at 28 February 2025 will be eligible for the dividend.

 

Board composition

 

The board consist of four Directors, three of which are independent from the Manager.

 

Ordinary share issue

 

The offer for subscription for Ordinary Shares that opened on 22 September 2023 and closed on 29 August 2024 received aggregate subscriptions from the issue of Ordinary shares of £7.9 million. On 14 October 2024 a new prospectus was launched for a further offer for subscription for Ordinary Shares, with the shares to be issued in the 2024/25 and 2025/26 tax years.

 

Developments since the period end

 

Raindog is an independent production company co-founded by Academy Award® winning actor Colin Firth and former music executive Ged Doherty. Since the period end, the Company has made a follow-on investment of £450,000 in Raindog Films Limited to support continued development in a number of ongoing and new productions.

 

Jan Ward

Chairman

5 December 2024


 

INTERIM MANAGEMENT REPORT

 

Venture Capital Investments

 

Portfolio developments

 

Calculus Capital Limited manages the Company's portfolio of venture capital investments. In general, Calculus Capital prefers investments to be of a sufficient size to enable them to play an influential role in helping the investee companies develop. Investments by the Company are primarily in equity but may also be by way of loan stock and/or preference shares which provide income to assist in paying dividends and provide a measure of risk mitigation.

 

As at 30 September 2024, the portfolio had 37 Qualifying Investments. An update on some of the portfolio's top investments has been provided below.

 

Home Team Content Limited ("Home Team")

Home Team Content is a UK-based film and television production company founded in 2021 by experienced and award-winning producers Dominic Buchanan and Bennett McGhee. The company focuses on working with filmmakers of colour and women filmmakers of any ethnicity. Home Team signed a 'first look' deal with Universal International Studios (UIS) in 2022 covering television productions which provides a contribution to company overheads as well as funding development on projects picked up by UIS. In June 2024, UIS confirmed its option to extend for a third year on the 'First Look' deal. The company currently has several TV and film projects in paid development with UIS, Netflix, BBC, and Film4.

 

Optalitix Limited

Optalitix offers a low-code SaaS product to insurers and financial institutions which allows business processes based on Excel to be transformed into robust online systems.  Optalitix has performed well during the last year with recurring revenue as at September 2024 up 46% year on year.  The pipeline for the last quarter of the year continues to look strong, as the company is clearly achieving a strong product-market fit in the specialty insurance underwriting market.

 

Fiscaltec Group Limited ("Fiscaltec")

Fiscaltec's proprietary solution analyses an organisation's financial transactions and supplier contacts, providing an independent overview of the effectiveness of the processes and controls encompassing spend. The company has continued to perform well during 2024, enjoying particular success upselling additional solutions to its existing list of very committed clients. Although the economic environment of the last year has meant that potential new customers have been cautious when making buying decisions, Fiscaltec is focusing its efforts on the new client pipeline in order to increase the rate of "new logo" wins and accelerate its growth further.

 

Brouhaha Entertainment Limited ("Brouhaha")

Brouhaha, based in London and Sidney, is a film and television production company founded by Academy Award® nominated producer Gaby Tana and experienced industry professionals Troy Lum and Andrew Mason. After the phenomenal success of the TV Series Boy Swallows Universe on Netflix which outperformed all expected metrics, Brouhaha is working on two other TV projects with Netflix - Lola in the Mirror and Love & Virtue.

 

Oxford BioTherapeutics Limited ("OBT")

OBT is a clinical stage oncology company, it's pipeline of novel immunotherapies is balanced between internal and externally partnered programs with big pharma companies such as Boehringer Ingelheim. In February 2024 AbbVie (NYSE:ABBV) completed its acquisition of Immunogen, previously a partner of OBT. Following the acquisition AbbVie took the decision to end Immunogen's extensive, and successful, partnership with OBT. Whilst this was initially disappointing, it resulted in a number of well-advanced drug programs reverting to OBT, allowing the company to seek new partners for those programs. This has generated significant interest and allowed OBT to re-partner for the programs, predominantly on better terms given the advances that had been made with Immunogen.

 

Rotageek Limited ("Rotageek")

Rotageek provides a workforce management solution, creating staff schedules using cloud-based technology, including auto scheduling, to optimise the schedules based on staffing need, employee wishes and regulatory working time limits. Rotageek is continuing to experience good growth with 25% increase in year-on-year ARR as at September 2024. The company has a strong pipeline of opportunities and is continuing to consider its strategic options which, with continuing strong sales, could lead to a sale of the company in or around 2025.

 

Riff Raff Entertainment Limited ("Riff Raff")

Riff Raff is a TV and film production company founded by Academy Award® nominated actor Jude Law and his creative partner Ben Jackson. The company has a film 'First Look' deal with New Republic Pictures (NRP), contributing to company overheads and funding development on projects picked up by NRP. The company has also signed a two-year 'First Look' TV deal with Newen for TV projects.

 

Maven Screen Media Limited ("Maven")
Maven was launched in 2020 by experienced producers, Academy Award® nominated Celine Rattray and Trudie Styler. The company focuses on female-focused films, television, and podcasts often with a social message.  In July, the film Unicorns had a positive UK theatrical release, with Netflix SVOD to follow during the year. Among other advanced projects, the film Eleanor the Great, which marks Scarlett Johansson's directorial debut and is financed by Sony, has finished all the shooting and is now in post-production.

Censo Biotechnologies Limited ("Axol")

Censo Biotechnologies Ltd (trading as Axol Bioscience) is a stem cells science company which develops and manufactures induced pluripotent stem cells (iPSCs) and provides related laboratory services. In June 2024, Axol raised £3.6 million through a fully subscribed round in a new senior class of equity and in October, Axol acquired Phenocell SAS, an iPSC company specialising in skin and retinal disorders, complementing Axol's current specialisation on neuroscience, pain and touch and cardiovascular disorders.  During 2024, Axol has been performing in line with budget, notwithstanding a challenging period for many other iPSC companies in the market.

Tagomics Limited ("Tagomics")
Tagomics continues to make excellent technical and commercial progress in the development of its comprehensive disease insight platform. Tagomics' pioneering platform seamlessly combines 'omics' technologies, including genomics (detecting mutations), epigenomics (studying chemical 'switches' on the genome), and fragmentomics (the analysis of DNA fragmentation patterns in the blood); the evidence this platform can deliver means that the company has already attracted significant partners and commercial clients. The company expects to launch further partnerships over the next 6 months.

 

Developments since the period end

 

As mentioned above, the Company invested an additional £450,000 in a follow-on investment into Raindog Films Limited which took place in October 2024.

 

Calculus Capital Limited
Investment Manager                             

5 December 2024        


INVESTMENT PORTFOLIO AS AT 30 SEPTEMBER 2024

- TOTAL FUND

 

% of Net Assets



Unquoted - loan stock

7%

Quoted and unquoted - ordinary and preference shares

61%

Unquoted - liquidity funds

21%

Net current assets

11%


100%



 

Asset class - % of Portfolio

 

Company

Book Cost

Market Valuation as at 30 September 2024

Multiple against book cost as at 30 September 2024

Multiple against book cost as 31 March 2024

Market Value Movement since 31 March 2024 

% of portfolio 

Qualifying Investments







Arctic Shores Limited

610

           610

1.00x

1.00x

0.0%

1.7%

Arecor Therapeutics plc

833

           274

0.33x

0.72x

-54.1%

0.7%

Blu Wireless Technologies Limited

833

        1,042

1.25x

1.07x

17.3%

2.8%

Brouhaha Entertainment Limited

1,331

        2,280

1.71x

1.88x

0.0%

6.2%

C4X Discovery Holdings Limited

598

           625

1.04x

0.47x

124.1%

1.7%

Censo Biotechnologies Limited

1,051

           909

0.86x

0.86x

0.0%

2.5%

Engaging Works Limited

 666

           666

1.00x

New

New

1.8%

Evoterra Limited

 1,215

           256

0.21x

0.21x

0.0%

0.7%

Fiscaltec Group Limited

 768

        1,275

1.66x

1.58x

5.0%

3.5%

Hinterview Limited

 800

           400

0.50x

0.59x

-15.6%

1.1%

Home Team Content Limited

 786

        1,763

2.24x

2.24x

0.0%

4.8%

Huma Therapeutics Limited (was eConsult Limited)

 262

           264

1.01x

1.00x

-64.8%

0.7%

Invizius Limited

 486

           340

0.70x

1.14x

-36.9%

0.9%

IPV Limited

 340

           409

1.20x

1.20x

0.0%

1.1%

Laverock Therapeutics Limited

 744

           744

1.00x

1.00x

0.0%

2.0%

Maven Screen Media Limited

 798

           909

1.14x

1.14x

0.0%

2.5%

Notify Technologies Limited

  628

           731

1.16x

1.16x

0.0%

2.0%

Open Energy Market Limited

200

           576

2.88x

2.56x

12.5%

1.6%

Optalitix Limited

1,347

        1,681

1.25x

1.31x

0.00%

4.6%

Oxford Biotherapeutics Limited

350

        1,773

5.07x

5.07x

0.0%

4.8%

Quai Administrations Limited

920

        1,186

1.29x

1.27x

1.2%

3.2%

Raindog Films Limited

396

           297

0.75x

1.00x

-25.0%

0.8%

Riff Raff Entertainment Limited

874

        1,848

2.11x

1.94x

9.2%

5.0%

Rota Geek Limited

1,530

        1,930

1.26x

1.21x

4.7%

5.3%

Scancell Holdings plc

378

           367

0.97x

0.69x

40.0%

1.0%

Tagomics Limited

909

           909

1.00x

1.00x

0.0%

2.5%

Thanksbox Limited

1,073

        1,177

1.10x

1.10x

0.0%

3.2%

Tozaro Limited (was MIP Diagnostics Limited) 

982

        1,078

1.10x

1.10x

0.0%

2.9%

Wazoku Limited

720

           718

1.00x

1.61x

-38.2%

2.0%

Wonderhood Limited

441

           723

1.64x

1.64x

0.0%

2.0%

Other*

1,216

383

0.31x

0.44x

-49.4%

1.0%








Total Qualifying Investments

24,085

          28,143



 

76.6%








Other non-Qualifying Investments







Aberdeen Sterling Liquidity Fund

2,707

        2,707

1.00x

1.00x

0.0%

7.4%

Fidelity Sterling Liquidity Fund

2,883

        3,171

1.10x

1.07x

2.6%

8.6%

Goldman Sachs Sterling Liquidity Fund

2,705

        2,705

1.00x

1.00x

0.0%

7.4%

Total other non-qualifying investments

8,295

8,583




 23.4%

Total investments

32,380

36,726




 

Net Current Assets less Creditors due after one year


3,201





Net Non-Current Assets less Creditors due after one year


1,362





Net Assets


41,289





 

 

*All individual investee companies with a market value of less than £0.15 million have been grouped together as "Other".

 


PRINCIPAL RISKS

 

The principal risks facing the Company remain the same as those detailed on page 32 of the Annual Report and Accounts for the period ended 31 March 2024.

 

Brexit is still causing uncertainty however it remains our view that our portfolio companies are not experiencing material difficulties as a result of the political situation.

 

Regulatory and Compliance risks remain prevalent as the Company is listed on The London Stock Exchange and is required to comply with the listing rules of the Financial Conduct Authority, as well as with the Companies Act, Accounting Standards and various other legislations.

 

The main risks faced by the Company include, but are not limited to, loss of approval as a venture capital trust and other regulatory breaches, risks of making and realising qualifying investments, liquidity/marketability risk, changes in legislation/taxation, engagement of third-party advisers, market price risk and credit risk.

 

GOING CONCERN

 

After making enquiries, and having reviewed the portfolio, balance sheet and projected income and expenditure for the next twelve months, the Directors have a reasonable expectation that the Company has adequate resources to continue in operation for the foreseeable future. The Directors have therefore adopted the going concern basis in preparing these condensed financial statements.

 

 

 

 

DIRECTORS' RESPONSIBILITY STATEMENT

 

The Directors confirm that to the best of their knowledge the half-yearly financial report, which has been prepared in accordance with the UK Listing Authority Disclosure and Transparency Rules ("DTR") and in accordance with the Financial Reporting Council's Financial Reporting Standard 104: 'Interim Financial Reporting' gives a true and fair view of the assets, liabilities, financial position and the net return of the Company as at 30 September 2024.

 

The Directors confirm that the Chairman's Update, the Investment Management report, the disclosures above and notes 10 and 11, include a fair review of the information required by DTR 4.2.7R, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements and a description of the principal risks and uncertainties for the remaining six months of the financial year, and DTR 4.2.8R.

 

The Directors of Calculus VCT plc are:

Jan Ward

Janine Nicholls

Hemant Mardia

John Glencross

 

By order of the Board

 

 

Jan Ward

Chairman,

5 December 2024

CONDENSED INCOME STATEMENT

FOR THE PERIOD FROM 1 APRIL 2024 TO 30 SEPTEMBER 2024 (UNAUDITED)

 

 



6 Months Ended

6 Months Ended

13 Months Ended



30 September 2024

31 August 2023

31 March 2024*



Revenue

Capital 

Total

Revenue

Capital

Total

Revenue

Capital

 

Total



 Return

 Return

Return

 Return

Return

 Return

Return

Return

Total


Note

 £'000

 £'000

 £'000

 £'000

 £'000

 £'000

 £'000

 £'000

 £'000

 

 

Investment holding losses

8

-

(75)

(75)

-

(370)

(370)

-

(235)

(235)

 

(Loss)/gain on disposal of investments

 

8

 

 

-

 

 

(859)

 

 

(859)

 

 

-

 

 

1

 

 

1

 

 

-

 

 

-



-



 

 

 







Income


401

-

401

296

-

296

726

-

726



 

 

 







Investment management fee


(89)

(267)

(356)

(80)

(239)

(319)

(175)

(523)

(698)

Other operating expenses


(161)

-

(161)

(152)

-

(152)

(328)

-

(328)



 

 

 







(Loss)/profit on ordinary activities before taxation



151


(1,201)


(1,050)

 

64

 

(608)

 

(544)


223

 

(758)

 

(535)


 

 

 

 







Taxation on ordinary activities

3

-

-

-

-

-

-

-

-

-


 

 

 

 







(Loss)/profit for the period


151

(1,201)

(1,050)

64

(608)

(544)

223

(758)

(535)


 

 

 

 







Basic and diluted deficit per new Ordinary share

 

2

 

0.22p

 

(1.74)p

 

(1.52)p

 

0.11p

 

(1.04)p

 

(0.93)p

 

0.37p

 

(1.26)p

 

(0.89)p



 

 

 







*These figures are extracts from audited accounts. The notes form an integral part of these Accounts.

 

The supplementary revenue return and capital return columns are both prepared in accordance with the Association of Investment Companies ("AIC") Statement of Recommended Practice ("SORP"). No operations were acquired or discontinued during the period. All items in the above statements derive from continuing operations. There were no recognised gains or losses other than those passing through the Income Statement. The notes form an integral part of these condensed financial statements.

 

 

 

 



 

CONDENSED STATEMENT OF CHANGES IN EQUITY

FOR THE PERIOD FROM 1 APRIL 2024 TO 30 SEPTEMBER 2024 (UNAUDITED)

 

 


 

 

Non-distributable reserves

Distributable reserves

 


 

Share

 

Capital

Capital 

Capital 

 

 


Share

Premium

Special 

Redemption

Reserve 

Reserve 

Revenue 

 


Capital

Account

Reserve 

Reserve

Realised 

Unrealised 

Reserve 

Total 


£'000

£'000

£'000 

£'000 

£'000 

£'000 

£'000 

£'000 

For the 6 months to 30 September 2024

 

 

 

 

 

 

 

 

1 April 2024

634

23,057

14,848

89

(1,918)

4,074

(1,719)

39,065

Investment holding losses

-

-

-

-

-

(75)

-

(75)

Loss on disposal of investments

-

-

-

-

(859)

-

-

(859)

New share issue

96

5,752

-

-

-

-

-

5,848

Expenses of share issue

-

(113)

-

-

-

-

-

(113)

Share buybacks for cancellation

(8)

-

(472)

8

-

-

-

(472)

Management fee allocated to capital

-

-

-

-

(267)

-

-

(267)

Increase in accrual of IFA Commission

-

(26)

-

-

-

-

-

(26)

Revenue return after tax

-

-

-

-

-

-

151

151

Dividends paid (note 9)

-

-

(1,963)

-

-

-

-

(1,963)

Transfer of previously unrealised loss to realised

 

-

 

-

 

-

 

-

 

(347)

 

347

 

-

 

-

30 September 2024

722

28,670

12,413

97

(3,391)

4,346

(1,568)

41,289

For the 6 months to 31 August 2023









1 March 2023

523

14,924

17,832

69

(1,414)

4,328

(1,942)

34,320

Investment holding losses

-

-

-

-

-

(370)

-

(370)

Gain on disposal of investments

-

-

-

-

1

-

-

1

New share issue

97

6,235

-

-

-

-

-

6,332

Expenses of share issue

-

(87)

-

-

-

-

-

(87)

Share buybacks for cancellation

(3)

-

(205)

3

-

-

-

(205)

Management fee allocated to capital

-

-

-

-

(239)

-

-

(239)

Increase in accrual of IFA Commission

-

(30)

-

-

-

-

-

(30)

Revenue return after tax

-

-

-

-

-

-

64

64

Dividends paid (note 9)

-

-

(1,789)

-

-

-

-

(1,789)

Transfer of previously unrealised gain to realised

-

-

-

-

19

(19)

-

-

31 August 2023

617

21,042

15,838

72

(1,633)

3,939

(1,878)

37,997

 

 

 

 

 

 



 

 

 

 

 

 

CONDENSED STATEMENT OF CHANGES IN EQUITY

(CONTINUED)

 


 

 

 

 

 

 

 

 

Non-distributable reserves

 

 

 

 

 

 

 

Distributable reserves


 


Share


Capital

Capital 

Capital 



 

Share

Premium

Special 

Redemption

Reserve 

Reserve 

Revenue 


 

Capital

Account

Reserve 

Reserve

Realised 

Unrealised 

Reserve 

Total 

 

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000

For the 13 months to 31 March 2024*

 

 

 

 

 

 

 

 

1 March 2023

523

14,924

17,832

69

(1,414)

4,328

(1,942)

34,320

Investment holding losses

-

-

-

-

-

(235)

-

(235)

New share issue

8,308

-

-

-

-

-

8,439

Expenses of share issue

(163)

-

-

-

-

-

(163)

Share buybacks for cancellation

-

(1,195)

20

-

-

-

(1,195)

Management fee allocated to capital

-

-

-

(523)

-

-

(523)

Decrease in accrual of IFA commission

(12)

-

-

-

-

-

(12)

Revenue return after tax

-

-

-

-

-

-

223

223

Dividends paid

-

(1,789)

-

-

-

-

(1,789)

Transfer of previously unrealised losses to realised

-

-

-

19

(19)

-

-

31 March 2024

634

23,057

14,848

89

(1,918)

4,074

(1,719)

39,065

 

* These figures are extracts from audited accounts. The notes form an integral part of these Accounts.

 

 



 

CONDENSED BALANCE SHEET

AS AT 30 SEPTEMBER 2024

(UNAUDITED)



30 September 2024 

31 August 2023 

31 March 2024* 

 

Note

£'000

£'000

£'000

 


 



 


 



Fixed assets


 



Investments held at fair value through profit or loss

8

36,726

35,386

37,914

Deferred sales awaiting settlement


1,234

53

46

Deferred fixed interest awaiting settlement


250

-

-

 


38,210

35,439

37,960

 





Current assets





Debtors


314

391

451

Cash at bank and on deposit


3,185

2,634

1,124



3,499

3,025

1,575

 





Creditors: amounts falling due within one year

Creditors


 

(298)

 

(321)

 

(357)

 





Net current assets


3,201

2,704

1,218

 





Total assets less current liabilities


41,411

38,143

39,178

 





Creditors: amounts falling due after more than one year





IFA trail commission


(122)

(146)

(113)

 





Total net assets


41,289

37,997

39,065

 





Capital and reserves


 



Called-up share capital

6

722

617

634

Share premium account


28,670

21,042

23,057

Special reserve


12,413

15,838

14,848

Capital redemption reserve


97

72

89

Capital reserve - realised


(3,391)

(1,633)

(1,918)

Capital reserve - unrealised


4,346

3,939

4,074

Revenue reserve


(1,568)

(1,878)

(1,719)

Total shareholders' funds


41,289

37,997

39,065

 





Net asset value per new Ordinary share - basic and diluted

4

57.20p

61.55p

61.58p

 

* These figures are extracts from audited accounts. The notes form an integral part of these condensed financial statements.

 

CONDENSED STATEMENT OF CASH FLOW

FOR TO THE PERIOD FROM 1 APRIL 2024 TO 30 SEPTEMBER 2024

(UNAUDITED)



6 Months 

6 Months 

13 Months



Ended 

Ended 

 Ended 



30 September 

31 August 

31 March



2024 

2023 

2024*


Note

£'000 

£'000 

£'000 

 





 





Cash flow from operating activities


 



Investment income received


213

165

395

Deposit interest received


43

31

52

Investment management fees paid


(384)

(292)

(626)

Operating expenses


(172)

(190)

(362)

Net cash flow from operating activities

5

(300)

(286)

(541)

 





Cash flow from investing activities





Purchase of investments


(1,309)

(5,112)

(7,815)

Sale of investments


400

20

460

Net cash flow from investing activities


(909)

(5,092)

(7,355)

 





Cash flow from financing activities





Shares issued


5,574

6,057

8,165

Expenses of share issues


(113)

(81)

(188)

IFA trail commission


(29)

(25)

(27)

Share buybacks for cancellation


(473)

(205)

(1,196)

Equity dividend paid

9

(1,689)

(1,514)

(1,514)

Net cash flow from financing activities


3,270

4,232

5,240

Increase/(decrease) in cash and cash equivalents


2,061

(1,146)

(2,656)

Opening cash and cash equivalents


1,124

3,780

3,780

Net cash increase/(decrease)


2,061

(1,146)

(2,656)

Closing cash and cash equivalents


3,185

2,634

1,124

* These figures are extracts from audited accounts.  The notes form an integral part of these Accounts.


CONDENSED NOTES TO THE ACCOUNTS

 

1. Nature of Financial Information

 

The Company applies FRS 102 and the Association of Investment Companies ("AIC") SORP for its financial period ended September 2024 in its Financial Statements. The financial statements for the six months to 30 September 2024 have therefore been prepared in accordance with FRS 104 "Interim Financial Reporting". The condensed financial statements have been prepared on the same basis as the accounting policies set out in the statutory accounts for the period ended 31 March 2024.

The financial information contained in this Half Year Report and Accounts and the comparative figures for the financial year ended 31 March 2024 are not the Company's statutory accounts for the financial period as defined in the Companies Act 2006. The financial information for the periods ended 30 September 2024 and 31 August 2023 have not been audited.

The Annual Report and Financial Statements for the financial year ended 31 March 2024 have been delivered to the Registrar of Companies. The report of the auditors was: (i) unqualified; (ii) did not include a reference to any matters which the auditors drew attention by way of emphasis without qualifying the report; and (iii) did not contain statements under section 498 (2) and (3) of the Companies Act 2006.

The financial statements have been prepared on a going concern basis and on the basis that approval as an investment trust company will continue to be met.

 

 

2. Return per Share (Basic and diluted)

 


6 Months Ended

6 Months Ended

13 Months Ended


30 September 2024

31 August 2023

31 March 2024


Revenue 

Capital

Total

Revenue

Capital

Total 

Revenue 

Capital

Total


pence 

pence

pence

pence

pence

pence 

pence 

pence

pence











Return per Ordinary share

 

0.22

 

(1.74)

 

(1.52)

 

0.11

 

(1.04)

 

(0.93)

 

0.37

 

(1.26)

 

(0.89)

 

 

New Ordinary shares

 

 

Revenue return per Ordinary share is based on the net revenue gain on ordinary activities after taxation of £150,730 (31 August 2023: gain £64,012, 31 March 2024: gain £223,351) and on 69,107,223 (31 August 2023: 58,347,452, 31 March 2024: 60,236,611) Ordinary shares, being the weighted average number of Ordinary shares in issue during the period.

 

Capital return per Ordinary share is based on the net capital loss for the period of £1,200,498 (31 August 2023: loss £608,033, 31 March 2024: loss £758,656) and on 69,107,223 (31 August 2023: 58,347,452, 31 March 2024: 60,236,611) Ordinary shares, being the weighted average number of Ordinary shares in issue during the period.

 

Total return per Ordinary share is based on the net loss on ordinary activities for the period of £1,049,768 (31 August 2023: loss £544,021, 31 March 2024: loss £535,305) and on 69,107,223 (31 August 2023: 58,347,452, 31 March 2024: 60,236,611) Ordinary shares, being the weighted average number of Ordinary shares in issue during the period.

 

 

3. Taxation on Ordinary Activities

 

The estimated effective tax rate at the period end is 0 per cent. This remains unchanged from the prior year end.

 

 

 

4. Net Asset Value per Share

 


30 September

31 August

31 March


2024

2023

2024


Pence

Pence

Pence





Net asset value per new Ordinary share

57.20

61.55

61.58

 

The basic net asset value per new Ordinary share is based on net assets (including current period revenue) of £41,288,617 (31 August 2023: £37,997,043, 31 March 2024: £39,064,804) and on 72,181,123 (31 August 2023: 61,733,566, 31 March 2024: 63,441,389) Ordinary shares, being the number of new Ordinary shares in issue at the period end.

 

 

 

 

5. Reconciliation of Net Profit before Tax to Cash Flow from Operating Activities

 


30 September 

31 August 

31 March 


2024 

2023 

2024 


£'000 

£'000 

£'000 


 



Loss on ordinary activities before tax

(1,050)

(544)

(535)

Loss on investments

934

369

235

Increase in debtors

(106)

(97)

(227)

(Decrease)/increase in creditors

(46)

(14)

39

Non cash movement

(32)

-

(53)

 

 



Cash flow from operating activities

(300)

(286)

(541)

 

 

6. Called up share capital

 

 

30 September

 

 

2024

 

Number

£'000

 



Ordinary shares of 1p each

72,181,123

722

 

In April 2024 the Company issued 5,257,265 Ordinary shares for a total consideration of £3,176,829. Also in April 2024, the Company bought back for cancellation 833,854 Ordinary shares for a total consideration of £472,373. In July 2024, 2,992,248 Ordinary shares were issued for a total consideration of £1,877.375. In August 2024, 463,382 Ordinary shares were issued under the Dividend Re-Investment Scheme. Also in August 2024, 860,693 Ordinary shares were issued for a total consideration of £519,788.

 

Following the issues and cancellation noted above there were 72,181,123 Ordinary shares in issue as at 30 September 2024.

 

 

7. Contingent assets and contingent liabilities

 

There were no contingent assets or contingent liabilities in existence at 30 September 2024 (31 August 2023: £nil, 31 March 2024: £nil).

 



 

8. Fair Value Hierarchy

 

Investments held at fair value through profit or loss are valued in accordance with IPEV guidelines.

 

The valuation method used will be the most appropriate valuation methodology for an investment within its market, with regard to the financial health of the investment and the IPEV guidelines. As required by the Standard, an analysis of financial assets and liabilities, which identifies the risk of the Company's holding of such items is provided. The Standard requires an analysis of investments carried at fair value based on the reliability and significance of the information used to measure their fair value.

 

In order to provide further information on the valuation techniques used to measure assets carried at fair value, we have categorised the measurement basis into a "fair value hierarchy" as follows:

 

-    Quoted market prices in active markets - "Level 1"

Inputs to Level 1 fair values are quoted prices for identical asset in an active market. Quoted in an active market in this context means quoted prices are readily and regularly available and those prices represent actual and regularly occurring market transactions on an arm's length basis. The quoted price is usually the current bid price. The Company's investments in AIM quoted equities and money market funds are classified within this category.

 

-    Valued using models with significant observable market inputs - "Level 2"

Inputs to Level 2 fair values are inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly.

 

-    Valued using models with significant unobservable market inputs - "Level 3"

Inputs to Level 3 fair values are unobservable inputs for the asset. Unobservable inputs may have been used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset at the measurement date (or market information for the inputs to any valuation models). As such, unobservable inputs reflect the assumptions the Company considers that market participants would use in pricing the asset. The Company's unquoted equities and loan stock are classified within this category. Unquoted investments are valued in accordance with the IPEV guidelines.

 

 


Level 1

Level 2

Level 3

Total

Investments

£'000

£'000

£'000

£'000

 





 





Opening book cost

11,106

-

22,734

33,840

Opening unrealised appreciation/(depreciation)

 

(1,079)

 

-

 

5,153

 

4,074

Opening fair value

10,027

-

27,887

37,914


 

 

 

 

Movements in the period:

 

 

 

 

Purchase at cost

-

-

1,342

1,342

Sales - proceeds

-

-

(1,596)

(1,596)

Sales - realised losses on sales

-

-

(859)

(859)

Prior year unrealised losses realised during the period

 

(2)

 

-

 

(345)

 

(347)

Transfer from Level 1 to Level 3

(1,098)

-

1,098

-

Unrealised investment gains/(losses)

361

-

(89)

272

Closing fair value

9,288

-

27,438

36,726


 

 

 

 

Closing book cost

10,006

-

22,374

32,380

Closing unrealised appreciation/(depreciation)

 

(718)

 

-

 

5,064

 

4,346

Closing fair value

9,288

-

27,438

36,726






 

 

 

9. Dividends

 

For the period ended 31 March 2024, the Company declared a final dividend of 2.77p per share on 70,857,048 eligible shares amounting to £1,962,732. The dividend was paid on 29 August 2024.

 

Of the total number of eligible shares due this dividend, 60,975,166 were paid in cash, totalling £1,689,005. The remaining shares elected to participate in the Dividend Re-Investment Scheme. As a result, a further 463,382 Ordinary Shares were issued at a value of £273,727.

 

 

10. Transactions with Related Parties

 

John Glencross, a Director of the Company, is considered to be a related party due to his position as Chief Executive and a director of Calculus Capital Limited, the Company's Investment Manager.

 

Calculus Capital Limited receives an investment manager's fee from the Company. For the 6 months to 30 September 2024, Calculus Capital Limited earned £355,572 of Management Fees. (31 August 2023: £319,340; 31 March 2024: £697,848). Calculus Capital Limited also earned a company secretarial fee of £9,000 (31 August 2023: £9,000; 31 March 2024: £19,500).

 

At 30 September 2024, £189,632 was due to Calculus Capital Limited (31 August 2023: £172,871; 31 March 2024: £219,178) in relation to unpaid investment manager's and company secretarial fees.

 

Calculus Capital Limited took on the expenses cap on 15 December 2015. In the 6 months to 30 September 2024, Calculus Capital Limited did not contribute towards the expenses. (31 March 2024: contributed £nil).

 

11. Transactions with Investment Managers

 

John Glencross, a Director of the Company, is Chief Executive and a director of Calculus Capital Limited, the Company's Manager. He does not receive any remuneration from the Company. He is a director of Brouhaha Entertainment Limited, Home Team Content Limited, Maven Screen Media Limited, Raindog Films Limited, Riff Raff Entertainment Limited and Wonderhood Studios Limited.

 

Calculus Capital receives fees from certain portfolio companies. The aggregate net amounts received by Calculus Capital Limited for any monitoring, provision of a director and arrangement fees, as appropriate, from the investee companies was £444,000 for the period to 30 September 2024 (£396,000 to 31 August 2023; £1,099,000 to 31 March 2024).

 

12. Post balance sheet events

 

Since the period end, the Company has made follow on investments of £450,000 in Raindog Films Limited

 

The Company also bought back and cancelled 517,241 shares in October 2024 for an aggregate consideration of £290,276.

 

 

 

 

 

  



 

COMPANY INFORMATION

 

 

Directors

Fund Administrator

Jan Ward
Janine Nicholls

Waystone Administration Solutions (UK) Limited

John Glencross

Broadwalk House

Hemant Mardia

Southernhay West


Exeter EX1 1TS





Registered Office

Auditors

12 Conduit Street

Moore Kingston Smith

London

6th Floor, 9 Appold Street

W1S 2XH

London EC2A 2AP

Telephone: 020 7493 4940



Broker

Company Number

Singer Capital Markets

07142153

1 Bartholomew Lane


London EC2N 2AX

 



Venture Capital Investments Manager

Registrars

And Company Secretary

The City Partnership (UK) Limited

12 Conduit Street

The Mending Rooms

London

Park Valley Mills

W1S 2XH

Meltham Road

Telephone: 020 7493 4940

Huddersfield

Website: www.calculuscapital.com

HD4 7BH





Sponsor

Beaumont Cornish Limited

10th Floor, 30 Crown Pl, Hackney
London EC2M 2SJ

 










Legal Entity Identifier: 2138005SMDWLMMNPVA90

 

Printed copies of the Calculus VCT plc Half Yearly Report for the six months ended 30 September 2024 have not been posted to shareholders. However, a copy can be found on the following website: https://calculuscapital.com/products/calculus-vct/investor-information/

 

 

For further information, please contact:

 

Calculus Capital Limited

Telephone: 020 7493 4940

 

Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on this announcement (or any other website) are incorporated into, or form part of, this announcement.

 

END

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR UPGUPPUPCGMA
Calculus Vct (LSE:CLC)
過去 株価チャート
から 11 2024 まで 12 2024 Calculus Vctのチャートをもっと見るにはこちらをクリック
Calculus Vct (LSE:CLC)
過去 株価チャート
から 12 2023 まで 12 2024 Calculus Vctのチャートをもっと見るにはこちらをクリック